The drugs we deserve

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 110, Issue 11, 2003, Pages 969-970

  Thornton, Jim ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ATOSIBAN; CALCIUM CHANNEL BLOCKING AGENT; NEW DRUG; NIFEDIPINE; RECEPTOR ANTIBODY; RITODRINE;

COCHRANE LIBRARY; EDITORIAL; HUMAN; INTRAUTERINE GROWTH RETARDATION; PREECLAMPSIA; PREGNANCY TERMINATION; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; UTERUS CONTRACTILITY;

CLINICAL TRIALS; DRUG DESIGN; FEMALE; HUMANS; LEGISLATION, DRUG; PHYSICIAN'S PRACTICE PATTERNS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 0242317261     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2003.11111.x     Document Type: Editorial

References (3)

1. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. Br J Obstet Gynaecol. 108:2001;133-142.
2. Goodwin T.M., Valenzuela G.J., Silver H., Creasy G. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstet Gynecol. 88:1996;331-336.
3. King JF, Flenady VJ, Papatsonis DNM, Dekker GA, Carbonne B. Calcium channel blockers for inhibiting preterm labour (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software, 2003.